NCT06353646

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

Efficacy and Safety Trial of XH001 (Neoantigen Cancer Vaccine) Sequential Combination With Immunocheckpoint Inhibitor and Chemotherapy in Adjuvant Therapy for Patients With Resected Pancreatic Cancer

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 28 (estimated)
• Sponsor: Wu Wenming · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a single-center, open label, single-arm, investigator-initiated study to evaluate the efficacy and safety of XH001 (neoantigen cancer vaccine) sequential combination with immunocheckpoint inhibitor and chemotherapy in pancreatic cancer patients following surgical resection.

Conditions

• Pancreatic Cancer

Interventions

Type	Name	Description
BIOLOGICAL	XH001	XH001 will be administered 12 weeks post-tumor resection (+/- 2 weeks)
DRUG	Ipilimumab Injection	Ipilimumab will be administered 12 weeks post-tumor resection (+/- 2 weeks)
DRUG	Sintilimab injection	Sintilimab will be administered 12 weeks post-tumor resection (+/- 2 weeks)
DRUG	Chemotherapy	gemcitabine + capecitabine

Timeline

• Start date: 2024-03-12
• Primary completion: 2026-06-01
• Completion: 2026-12-01
• First posted: 2024-04-09
• Last updated: 2026-02-13

Locations

1 site across 1 country: China